Skip to main content
Journal cover image

Renal Dysfunction in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial.

Publication ,  Journal Article
Patel, RB; Mehta, R; Redfield, MM; Borlaug, BA; Hernandez, AF; Shah, SJ; Dubin, RF
Published in: J Card Fail
March 2020

BACKGROUND: Patients with heart failure with preserved ejection fraction (HFpEF) and chronic kidney disease (CKD) represent a high-risk phenotype. The Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure with Preserved Ejection Fraction (RELAX) trial enrolled a high proportion of CKD participants, allowing investigation into differences in HFpEF by CKD status. METHODS AND RESULTS: Among 212 participants, we investigated the associations of CKD with biomarkers, cardiac structure, and exercise capacity, and identified predictors of change in estimated glomerular filtration rate (eGFR) over trial follow-up. CKD participants (eGFR ≤60 mL/min/1.73m2) were older, had more comorbidities, and had worse diastolic function. Lower eGFR was associated with higher levels of endothelin-1, N-terminal pro-B-type natriuretic peptide, aldosterone, uric acid, and biomarkers of fibrosis (P < .05 for all). Whereas lower eGFR was associated with worse peak oxygen consumption (VO2) after adjustment for demographics, clinical comorbidities, exercise modality, ejection fraction, and chronotropic index (β coefficient per 1 SD decrease in eGFR: -0.61, 95% CI: -1.01, -0.22, P = .002), this association was attenuated after further adjustment for hemoglobin (β coefficient: -0.26, 95% CI: -0.68, 0.16, P = .22). Hemoglobin mediated 35% of the association between eGFR and peak VO2. Sildenafil therapy was independently associated with worsening eGFR over the trial (β coefficient: -2.79, 95% CI: -5.34, -0.24, P = .03). CONCLUSION: Renal dysfunction in HFpEF is characterized by echocardiographic and biomarker profiles indicative of more advanced disease, and reduced hemoglobin is a strong mediator of the association between renal dysfunction and low exercise capacity. Sildenafil therapy was associated with worsening of renal function in RELAX.

Duke Scholars

Published In

J Card Fail

DOI

EISSN

1532-8414

Publication Date

March 2020

Volume

26

Issue

3

Start / End Page

233 / 242

Location

United States

Related Subject Headings

  • Stroke Volume
  • Sildenafil Citrate
  • Kidney Diseases
  • Humans
  • Heart Failure
  • Diastole
  • Cardiovascular System & Hematology
  • 3202 Clinical sciences
  • 3201 Cardiovascular medicine and haematology
  • 1110 Nursing
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Patel, R. B., Mehta, R., Redfield, M. M., Borlaug, B. A., Hernandez, A. F., Shah, S. J., & Dubin, R. F. (2020). Renal Dysfunction in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial. J Card Fail, 26(3), 233–242. https://doi.org/10.1016/j.cardfail.2020.01.003
Patel, Ravi B., Rupal Mehta, Margaret M. Redfield, Barry A. Borlaug, Adrian F. Hernandez, Sanjiv J. Shah, and Ruth F. Dubin. “Renal Dysfunction in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial.J Card Fail 26, no. 3 (March 2020): 233–42. https://doi.org/10.1016/j.cardfail.2020.01.003.
Patel RB, Mehta R, Redfield MM, Borlaug BA, Hernandez AF, Shah SJ, et al. Renal Dysfunction in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial. J Card Fail. 2020 Mar;26(3):233–42.
Patel, Ravi B., et al. “Renal Dysfunction in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial.J Card Fail, vol. 26, no. 3, Mar. 2020, pp. 233–42. Pubmed, doi:10.1016/j.cardfail.2020.01.003.
Patel RB, Mehta R, Redfield MM, Borlaug BA, Hernandez AF, Shah SJ, Dubin RF. Renal Dysfunction in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial. J Card Fail. 2020 Mar;26(3):233–242.
Journal cover image

Published In

J Card Fail

DOI

EISSN

1532-8414

Publication Date

March 2020

Volume

26

Issue

3

Start / End Page

233 / 242

Location

United States

Related Subject Headings

  • Stroke Volume
  • Sildenafil Citrate
  • Kidney Diseases
  • Humans
  • Heart Failure
  • Diastole
  • Cardiovascular System & Hematology
  • 3202 Clinical sciences
  • 3201 Cardiovascular medicine and haematology
  • 1110 Nursing